Jenna L. Carter

599 total citations
18 papers, 396 citations indexed

About

Jenna L. Carter is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Jenna L. Carter has authored 18 papers receiving a total of 396 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 10 papers in Hematology and 4 papers in Cancer Research. Recurrent topics in Jenna L. Carter's work include Acute Myeloid Leukemia Research (10 papers), Histone Deacetylase Inhibitors Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Jenna L. Carter is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Histone Deacetylase Inhibitors Research (6 papers) and Protein Degradation and Inhibitors (5 papers). Jenna L. Carter collaborates with scholars based in United States and China. Jenna L. Carter's co-authors include Jeffrey W. Taub, Holly Edwards, Yubin Ge, Maik Hüttemann, Hasini A. Kalpage, Yongwei Su, Jay Yang, Stephen M. Stack, Lorinda K. Anderson and Jun Ma and has published in prestigious journals such as Blood, Cancer Research and Genetics.

In The Last Decade

Jenna L. Carter

17 papers receiving 392 citations

Peers

Countries citing papers authored by Jenna L. Carter

Since Specialization

Citations

This map shows the geographic impact of Jenna L. Carter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenna L. Carter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenna L. Carter more than expected).

Fields of papers citing papers by Jenna L. Carter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenna L. Carter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenna L. Carter. The network helps show where Jenna L. Carter may publish in the future.

Co-authorship network of co-authors of Jenna L. Carter

This figure shows the co-authorship network connecting the top 25 collaborators of Jenna L. Carter. A scholar is included among the top collaborators of Jenna L. Carter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenna L. Carter. Jenna L. Carter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress 2025 ·Journal of Experimental & Clinical Cancer Research ·Jenna L. Carter, Yongwei Su, (unknown), Jianlei Zhao, (unknown), Guan Wang, Holly Edwards, Lisa Polin, Juiwanna Kushner, (unknown), Kathryn White, Steven Buck, Maik Hüttemann, Joshua E. Allen, (unknown), Jay Yang, Jeffrey W. Taub, Yubin Ge	0
2	Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML 2024 ·Leukemia Research ·(unknown), Fangbing Liu, (unknown), Jenna L. Carter, Holly Edwards, Maik Hüttemann, Guan Wang, (unknown), Jeffrey W. Taub, Yue Wang, Yubin Ge	2
3	Salivary Cortisol Analysis in Collegiate Female Lacrosse Athletes 2023 ·International journal of exercise science ·Jenna L. Carter, Stephanie L. Mathews, (unknown), Jennifer A. Bunn	2
4	Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents 2023 ·Biochemical Pharmacology ·(unknown), (unknown), Jenna L. Carter, (unknown), MacKenzie A. Howard, Holly Edwards, Yubin Ge, Jeffrey W. Taub	4
5	Acquired resistance to venetoclax plus azacitidine in acute myeloid leukemia: In vitro models and mechanisms 2023 ·Biochemical Pharmacology ·Jenna L. Carter, Yongwei Su, (unknown), Jianlei Zhao, Guan Wang, MacKenzie A. Howard, Holly Edwards, Xun Bao, Jing Li, Maik Hüttemann, Jay Yang, Jeffrey W. Taub, Yubin Ge	9
6	Analysis of cortisol response and load in collegiate female lacrosse athletes: A pilot study 2022 ·Jenna L. Carter, Stephanie L. Mathews, Brad A. Myers, Jennifer A. Bunn, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
7	Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia 2022 ·Cells ·(unknown), Holly Edwards, Deying Wang, Shuang Liu, (unknown), Jenna L. Carter, Yue Wang, Jeffrey W. Taub, Guan Wang, Yubin Ge	5
8	Co-Targeting of HDAC, PI3K, and Bcl-2 Results in Metabolic and Transcriptional Reprogramming and Decreased Mitochondrial Function in Acute Myeloid Leukemia 2022 ·SSRN Electronic Journal ·(unknown), (unknown), Xinyu Li, Yongwei Su, Jenna L. Carter, Jun Ma, Hasini A. Kalpage, Maik Hüttemann, Holly Edwards, Guan Wang, Seongho Kim, Alan A. Dombkowski, Xun Bao, Jing Li, Jeffrey W. Taub, Yubin Ge	2
9	Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia 2022 ·Biochemical Pharmacology ·(unknown), (unknown), Xinyu Li, Yongwei Su, Jenna L. Carter, Jun Ma, Hasini A. Kalpage, Maik Hüttemann, Holly Edwards, Guan Wang, Seongho Kim, Alan A. Dombkowski, Xun Bao, Jing Li, Jeffrey W. Taub, Yubin Ge	11
10	Abstract 3785: ME-344, a novel isoflavone mitochondrial inhibitor, in combination with venetoclax constitutes a new metabolism-targeted approach to overcome resistance to Bcl-2 inhibition and standard of care treatment in AML 2022 ·Cancer Research ·(unknown), Yongwei Su, Shraddha Patel, Sandra E. Wiley, Zhanjun Hou, Jenna L. Carter, Hasini A. Kalpage, Maik Hüttemann, Connie C. Weng, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry H. Matherly, Sergej Konoplev, Jeffrey W. Taub, Marina Konopleva, Yubin Ge, Natalia Baran	1
11	A Novel Isoflavone, ME-344, Enhances Venetoclax Antileukemic Activity Against AML Via Suppression of Oxidative Phosphorylation and Purine Biosynthesis 2021 ·Blood ·(unknown), Yongwei Su, Sandra E. Wiley, Zhanjun Hou, Jenna L. Carter, Hasini A. Kalpage, Maik Hüttemann, Holly Edwards, Lisa Polin, Jing Li, Jay Yang, Larry H. Matherly, Jeffrey W. Taub, Yubin Ge	2
12	Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy 2020 ·Signal Transduction and Targeted Therapy ·Jenna L. Carter, (unknown), Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub, Yubin Ge	143
13	Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation 2020 ·Cancers ·Fangbing Liu, Hasini A. Kalpage, (unknown), Holly Edwards, Maik Hüttemann, Jun Ma, Yongwei Su, Jenna L. Carter, Xinyu Li, Lisa Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Guan Wang, Jeffrey W. Taub, Yubin Ge	29
14	Targeting mitochondrial respiration for the treatment of acute myeloid leukemia 2020 ·Biochemical Pharmacology ·Jenna L. Carter, (unknown), Hasini A. Kalpage, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub, Yubin Ge	43
15	Three-dimensional alginate hydrogels for radiobiological and metabolic studies of cancer cells 2018 ·Colloids and Surfaces B Biointerfaces ·Graham Read, Natsuko Miura, Jenna L. Carter, (unknown), Kazutoshi Yamamoto, Nallathamby Devasahayam, Jason Cheng, Kevin Camphausen, Murali C. Krishna, Aparna H. Kesarwala	12
16	The PBS-12SF Cell Line: Development of an Alternative Cell Line for Influenza Vaccine Production 2016 ·Journal of Vaccines & Vaccination ·Kelly R. B. Sporer, Jenna L. Carter, Paul M. Coussens	1
17	Enhanced production of human influenza virus in PBS-12SF cells with a reduced interferon response 2015 ·Human Vaccines & Immunotherapeutics ·Mónica Carvajal-Yepes, Kelly R. B. Sporer, Jenna L. Carter, Christopher J. Colvin, Paul M. Coussens	4
18	High-Resolution Crossover Maps for Each Bivalent of Zea mays Using Recombination Nodules 2003 ·Genetics ·Lorinda K. Anderson, (unknown), (unknown), Jenna L. Carter, (unknown), (unknown), (unknown), Stephen M. Stack	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact